FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380078275> ?p ?o ?g. }

• W4380078275 endingPage "728" @default.
• W4380078275 startingPage "728" @default.
• W4380078275 abstract "Introduction: The rapidly expanding treatment landscape for Chronic Lymphocytic Leukemia (CLL) calls for appropriate patient and treatment selection and sequencing with existing agents. Data describing CLL management are fragmented across different regions, with marked cross-country differences in treatment practices and patient outcomes. Therefore, we have established the observational study CREEK, CLL retrospective real-world evidence key data from the Middle East and North Africa, Asia, and Latin America. This interim analysis aimed to describe the patient and disease characteristics of CLL-treated (CLL-Tx) patients in international countries and CLL treatment-naïve (CLL-N) patients in the Gulf Cooperation Council (GCC) states. Methods: Data from 976 patients were collected, including 845 CLL-Tx patients who started treatment between 01 June 2016 and 12 months before data collection and a pilot cohort of 131 CLL-N patients. Patients’ demographics, disease characteristics, laboratory assessments, and comorbidities were recorded. Results: The average age for CLL-Tx and CLL-N was 63.5 and 63.4 years, respectively. Most patients were males, 66.7% in CLL-Tx and 71.0% in CLL-N. Around 11% of patients in CLL-Tx and 12% in CLL-N were current smokers. Most CLL-Tx (62%) had an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, and the same was for CLL-N (56.4%). As per the Cumulative Illness Rating Scale (CIRS), moderate to severe musculoskeletal (p < 0.0025), and endocrine-metabolic (p < 0.0001) comorbidities were more frequent in CLL-Tx. All laboratory parameters, except neutrophils and eGFR categories, showed a significant difference (p < 0.05) between CLL-Tx and CLL-N. The average days from diagnosis to enrollment were 475 and 59 days in CLL-Tx and CLL-N (p < 0.0001), respectively. Patients with CLL-Tx had a worse prognosis compared to CLL-N based on Rai and Binet Staging Scores (p < 0.0001). The testing rate for IGHV mutation status was low, with 23.5% in CLL-Tx and 38.9% in CLL-N, and the percentage of mutated IGHV was significantly lower (p = 0.0006) in CLL-Tx (9.8%) compared to CLL-N (26.7%). Whereas cytogenetic abnormalities (del “17p”—del “11q”—Complex karyotype), TP53 Aberrations, and cytogenetic abnormalities and TP53 aberrations (del “17p” and TP53 aberrations—TP53 aberrations without del “17p”) didn’t show a significant difference (p > 0.05) between CLL-Tx and CLL-N. Conclusions: This interim analysis demonstrated a preliminary understanding of the patients and disease characteristics of CLL-Tx and CLL-N patients. The study showed that patients with CLL-Tx and CLL-N had comparable demographic characteristics; however, patients with CLL-Tx had a higher prevalence of moderate to severe comorbidities, worse ECOG scores, worse prognosis based on Rai and Binet staging scores, and a lower prevalence of mutated IGHV. Keywords: chronic lymphocytic leukemia (CLL), CLL treatment naïve, cytogenetic abnormalities The research was funded by AstraZeneca UK Limited Conflict of interest P. Kantharaju Employment or leadership position: Pushpalata Kantharaju is an employee for AstraZeneca F. J Gonzalez Employment or leadership position: Francisco Gonzalez is an employee for AstraZeneca A. Ishikawa Employment or leadership position: Akemi Ishikawa is an employee for AstraZeneca" @default.
• W4380078275 created "2023-06-10" @default.
• W4380078275 creator A5011168903 @default.
• W4380078275 creator A5033325662 @default.
• W4380078275 creator A5033741101 @default.
• W4380078275 creator A5045924981 @default.
• W4380078275 creator A5058364259 @default.
• W4380078275 creator A5064207698 @default.
• W4380078275 creator A5065939953 @default.
• W4380078275 creator A5066720604 @default.
• W4380078275 creator A5067415856 @default.
• W4380078275 creator A5079995837 @default.
• W4380078275 creator A5091866608 @default.
• W4380078275 creator A5092127404 @default.
• W4380078275 date "2023-06-01" @default.
• W4380078275 modified "2023-10-12" @default.
• W4380078275 title "A MULTICENTER RETROSPECTIVE STUDY TO UNDERSTAND THE CLINICAL CHARACTERISTICS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: INTERIM RESULTS FROM THE CREEK STUDY" @default.
• W4380078275 doi "https://doi.org/10.1002/hon.3165_580" @default.
• W4380078275 hasPublicationYear "2023" @default.
• W4380078275 type Work @default.
• W4380078275 citedByCount "0" @default.
• W4380078275 crossrefType "journal-article" @default.
• W4380078275 hasAuthorship W4380078275A5011168903 @default.
• W4380078275 hasAuthorship W4380078275A5033325662 @default.
• W4380078275 hasAuthorship W4380078275A5033741101 @default.
• W4380078275 hasAuthorship W4380078275A5045924981 @default.
• W4380078275 hasAuthorship W4380078275A5058364259 @default.
• W4380078275 hasAuthorship W4380078275A5064207698 @default.
• W4380078275 hasAuthorship W4380078275A5065939953 @default.
• W4380078275 hasAuthorship W4380078275A5066720604 @default.
• W4380078275 hasAuthorship W4380078275A5067415856 @default.
• W4380078275 hasAuthorship W4380078275A5079995837 @default.
• W4380078275 hasAuthorship W4380078275A5091866608 @default.
• W4380078275 hasAuthorship W4380078275A5092127404 @default.
• W4380078275 hasBestOaLocation W43800782751 @default.
• W4380078275 hasConcept C126322002 @default.
• W4380078275 hasConcept C143998085 @default.
• W4380078275 hasConcept C166957645 @default.
• W4380078275 hasConcept C167135981 @default.
• W4380078275 hasConcept C23131810 @default.
• W4380078275 hasConcept C2776957806 @default.
• W4380078275 hasConcept C2777938653 @default.
• W4380078275 hasConcept C2778461978 @default.
• W4380078275 hasConcept C535046627 @default.
• W4380078275 hasConcept C61943457 @default.
• W4380078275 hasConcept C71924100 @default.
• W4380078275 hasConcept C72563966 @default.
• W4380078275 hasConcept C95457728 @default.
• W4380078275 hasConceptScore W4380078275C126322002 @default.
• W4380078275 hasConceptScore W4380078275C143998085 @default.
• W4380078275 hasConceptScore W4380078275C166957645 @default.
• W4380078275 hasConceptScore W4380078275C167135981 @default.
• W4380078275 hasConceptScore W4380078275C23131810 @default.
• W4380078275 hasConceptScore W4380078275C2776957806 @default.
• W4380078275 hasConceptScore W4380078275C2777938653 @default.
• W4380078275 hasConceptScore W4380078275C2778461978 @default.
• W4380078275 hasConceptScore W4380078275C535046627 @default.
• W4380078275 hasConceptScore W4380078275C61943457 @default.
• W4380078275 hasConceptScore W4380078275C71924100 @default.
• W4380078275 hasConceptScore W4380078275C72563966 @default.
• W4380078275 hasConceptScore W4380078275C95457728 @default.
• W4380078275 hasIssue "S2" @default.
• W4380078275 hasLocation W43800782751 @default.
• W4380078275 hasOpenAccess W4380078275 @default.
• W4380078275 hasPrimaryLocation W43800782751 @default.
• W4380078275 hasRelatedWork W1982430164 @default.
• W4380078275 hasRelatedWork W2023402573 @default.
• W4380078275 hasRelatedWork W2363503150 @default.
• W4380078275 hasRelatedWork W2381648486 @default.
• W4380078275 hasRelatedWork W2436084471 @default.
• W4380078275 hasRelatedWork W2442977450 @default.
• W4380078275 hasRelatedWork W2746117175 @default.
• W4380078275 hasRelatedWork W4241346962 @default.
• W4380078275 hasRelatedWork W64094104 @default.
• W4380078275 hasRelatedWork W3140988586 @default.
• W4380078275 hasVolume "41" @default.
• W4380078275 isParatext "false" @default.
• W4380078275 isRetracted "false" @default.
• W4380078275 workType "article" @default.